search

Active clinical trials for "Peripheral Vascular Diseases"

Results 341-350 of 1034

Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

Arterial Occlusive DiseasePeripheral Vascular Disease1 more

The primary purpose of this study was to assess the overall safety of different dose regimens of AMG0001 (HGF transferred via plasmid vector) as well as evaluate the improvement of blood perfusion in subjects with critical limb ischemia (CLI). This study also evaluated the improvement in wound healing without adverse effects on the quality of life, as well as the potential reduction of amputation, mortality and rest pain in the CLI population.

Completed19 enrollment criteria

Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent...

Intermittent ClaudicationPeripheral Vascular Disease

The purpose of this study is to evaluate if Niacin ER/Lovastatin, at two different doses, compared to diet control (this group will receive a tablet containing 50 mg. of immediate-release niacin) is a safe and effective medicine in subjects with leg pain caused by a narrowing of their leg arteries, a condition called intermittent claudication. At least 366 subjects with leg pain caused by a narrowing of their leg arteries will participate in this study. Niacin ER/Lovastatin is a combination of two FDA (United States Food and Drug Administration) approved cholesterol modifying medications: Niaspan® (extended-release niacin) and lovastatin, a statin (the same medicine found in Mevacor®). Niacin ER/Lovastatin was approved by the FDA under the name of Advicor® for use in the treatment of elevated cholesterol. The use of Niacin ER/Lovastatin in the treatment of peripheral arterial disease and symptomatic relief of intermittent claudication is considered investigational. An investigational use is one that is not approved by the FDA.

Completed11 enrollment criteria

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients...

Intermittent ClaudicationPeripheral Vascular Disease1 more

The purpose of this Phase 2 clinical research study is to examine the safety of an experimental gene transfer agent, Ad2/HIF-1α/VP16, and its ability to stimulate the growth of new blood vessels from existing blood vessels (a process called angiogenesis) in an attempt to improve the flow of blood in the legs of patients with peripheral arterial disease (PAD). Specifically, this study will enroll patients with severe intermittent claudication (IC) which is the stage of PAD in which a patient's walking ability is severely limited, causing pain in the legs upon exercise due to inadequate blood flow to the muscles of the lower limbs.

Completed32 enrollment criteria

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

Arterial Occlusive DiseasesPeripheral Vascular Diseases1 more

This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).

Completed5 enrollment criteria

Extract of Ginkgo Biloba (EGB 761) and Vascular Function

Intermittent ClaudicationPeripheral Vascular Disease

This study will determine if a highly standardized herbal extract of the leaves of the Ginkgo Biloba tree will benefit patients who have pain on walking due to narrowing of the arteries of the legs.

Completed17 enrollment criteria

Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial

Peripheral Artery DiseasePAD1 more

The GIFT pilot study will investigate the optimal subcutaneous dose and safety of subcutaneously administered unacylated ghrelin in older people with peripheral artery disease (PAD).

Completed11 enrollment criteria

Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease

Peripheral Arterial Disease

To evaluate the safety and effectiveness of the Cardio Flow FreedomFlow™ Orbital Circumferential Atherectomy System for atherosclerotic plaque removal and vessel compliance modification in de novo native target lesions in the peripheral vasculature of the lower extremities.

Completed36 enrollment criteria

Cell Therapy for Peripheral Arterial Disease and Diabetes

Peripheral Arterial DiseaseDiabetes Mellitus

This is a randomized controlled trial with blinding (for the observer who evaluates treatment goals). With two groups to study. A group of patients with conventional therapy for the treatment of PAD (Platelet antiaggregant, statin, cilostazol in case of claudication) and the other group of patients with conventional therapy for treatment of PAD plus cell therapy with objective to evaluate the microvascular effect after the application of cell therapy with a hematopoietic stem cell concentrate in patients with PAD with non-critical ischemia and Diabetes. Perform evaluations of the microcirculation by means of TcPO2 at 30, 60, 90 and 180 days after the experimental maneuver (cell therapy) and conventional therapy.

Completed10 enrollment criteria

Evaluate the Safety and Efficacy of a Steerable Catheter in the Treatment of Vascular Interventional...

Peripheral Vascular Diseases

This is a prospective, multicenter, single-arm clinical trial to evaluate safety and efficacy of a steerable catheter in the establishment of vascular intervention access. five centers participate in this study. The total enrollment number is 68. In the procedure of vascular interventional surgery or angiography diagnosis, the steerable catheter are used to building vascular interventional access. Evaluate the safety and efficacy of the product, by the observation and record the relative index of subjects intraoperative and postoperative (discharge) before and after 30 days .

Completed10 enrollment criteria

Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries

Peripheral Arterial Disease

A prospective, non-randomized, international, multi-center study to evaluate the safety and effectiveness of the Pantheris OCT-Imaging System to perform atherectomy in In-Stent Restenotic (ISR) lesions in lower extremity arteries.

Completed36 enrollment criteria
1...343536...104

Need Help? Contact our team!


We'll reach out to this number within 24 hrs